Weijing Kong

Weijing Kong

Auto-generated profile, based on publicly available information

Weijing Kong

Department of Pediatrics, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2022 in European Journal of Pharmacology
Verified
Journal Article
Closed access
WKWeijing Kong
Weijing Kong
CLCheng Lu
Cheng Lu
YDYingxue Ding
Yingxue Ding
YMYan Meng
Yan Meng

31 January 2017 in eneuro
Verified
Journal Article
Open access
PDF file
CHCiria C Hernandez
Ciria C Hernandez
WKWeijing Kong
Weijing Kong
NHNingning Hu
Ningning Hu
YZYujia Zhang
Yujia Zhang
WSWangzhen Shen
Wangzhen Shen
RMRobert L. Macdonald
Robert L. Macdonald
We identified ade novomissense mutation, P302L, in the γ-aminobutyric acid type A (GABAA) receptor γ2 subunit geneGABRG2in a patient with Dravet syndrome using targeted next-generation sequencing. The mutation was in the cytoplasmic portion of the transmembrane segment M2 of the γ2 subunit that faces the pore lumen. GABAAreceptor α1 and β3 subunits were coexpressed with wild-type (wt) γ2L or mutant γ2L(P302L) subunits in HEK 293T cells and cultured mouse cortical neurons. We measured currents using whole-cell and single-channel patch clamp techniques, surface and total expression levels using surface biotinylation and Western blotting, and potential structural perturbations in mutant GABAAreceptors using structural modeling. The γ2(P302L) subunit mutation produced an ∼90% reduction of whole-cell current by increasing macroscopic desensitization and reducing GABA potency, which resulted in a profound reduction of GABAAreceptor-mediated miniature IPSCs (mIPSCs). The conductance of the receptor channel was reduced to 24% of control conductance by shifting the relative contribution of the conductance states from high- to low-conductance levels with only slight changes in receptor surface expression. Structural modeling of the GABAAreceptor in the closed, open, and desensitized states showed that the mutation was positioned to slow activation, enhance desensitization, and shift channels to a low-conductance state by reshaping the hour-glass-like pore cavity during transitions between closed, open, and desensitized states. Our study revealed a novel γ2 subunit missense mutation (P302L) that has a novel pathogenic mechanism to cause defects in the conductance and gating of GABAAreceptors, which results in hyperexcitability and contributes to the pathogenesis of the genetic epilepsy Dravet syndrome.

22 July 2022 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Open access
MWMeimei Wang
Meimei Wang
FLFengqin Li
Fengqin Li
JZJing Zhang
Jing Zhang
CLCheng Lu
Cheng Lu
WKWeijing Kong
Weijing Kong
Background: Gaucher disease [GD], an autosomal recessive lysosomal storage disorder, is characterized by progressive lysosomal storage of glucocerebroside in macrophages predominantly in bone, bone marrow, liver, and spleen. Meta-analysis of global GD epidemiology was not available before this study. Methods: To provide a systematic review and meta-analysis of birth prevalence and prevalence of GD in multiple countries. MEDLINE and EMBASE databases were searched for original research articles on the epidemiology of GD from inception until July 21, 2021. Meta-analysis, adopting a random-effects logistic model, was performed to estimate the birth prevalence and prevalence of GD. Results: Eighteen studies that were screened of 1874 records were included for data extraction. The studies that fulfilled the criteria for inclusion involved 15 areas/countries. The global birth prevalence of GD was 1.5 cases [95% confidence interval: 1.0 to 2.0] per 100,000 live births. The global prevalence of GD was 0.9 cases [95% confidence interval: 0.7 to 1.1] per 100,000 inhabitants. Conclusions: This is the first comprehensive systematic review that presented quantitative data of GD global epidemiology. Quantitative data on global epidemiology of GD could be the fundamental to evaluate the global efforts on building a better world for GD patients.

19 July 2021 in Journal of Pediatric Endocrinology and Metabolism
Verified
Journal Article
Closed access
WKWeijing Kong
Weijing Kong
SWShanshan Wu
Shanshan Wu
JZJing Zhang
Jing Zhang
CLCheng Lu
Cheng Lu
YDYingxue Ding
Yingxue Ding
YMYan Meng
Yan Meng
Objectives: Mucopolysaccharidosis III, an autosomal recessive lysosomal storage disorder, is characterized by progressive mental retardation and behavioral problems. Meta-analysis of global mucopolysaccharidosis III epidemiology, which serves as a fundamental reference for public health decision-making, was not available prior to this study. To provide a systematic review and meta-analysis of birth prevalence of mucopolysaccharidosis III in multiple countries. Methods: MEDLINE and EMBASE databases were searched for original research articles on the epidemiology of mucopolysaccharidosis III from inception until 1st July, 2020. A checklist adapted from STROBE (STrengthening the Reporting of OBservational studies in Epidemiology) was used to assess the quality of all studies involved. Meta-analysis, adopting a random effects logistic model, was performed to estimate pooled birth prevalence of mucopolysaccharidosis III and its subtypes. Results: Twenty-five studies screened out of 1,826 records were included for data extraction. The pooled global mucopolysaccharidosis III birth prevalence was 0.76 cases (95% CI: 0.57–0.96) per 100,000 live births. The pooled global birth prevalence of mucopolysaccharidosis III subtypes (A, B, and C) was 0.52 cases (95% CI: 0.33–0.72), 0.21 cases (95% CI: 0.12–0.30) and 0.01 cases (95% CI: 0.005–0.02) per 100,000 live births, respectively. Conclusions: Based on the global population size (7.8 billion) and the life span of patients, there would be 12–19 thousand mucopolysaccharidosis III patients worldwide. To our knowledge, this is the first comprehensive systematic review that presented quantitative data fundamental for evidence-based public health decision-making by evaluating global epidemiology of mucopolysaccharidosis III.

1 December 2020 in European Journal of Pharmacology
Verified
Journal Article
Closed access
WKWeijing Kong
Weijing Kong
YYYanqing Yao
Yanqing Yao
JZJing Zhang
Jing Zhang
CLCheng Lu
Cheng Lu
YDYingxue Ding
Yingxue Ding
YMYan Meng
Yan Meng

15 July 2021 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
WKWeijing Kong
Weijing Kong
JZJing Zhang
Jing Zhang
CLCheng Lu
Cheng Lu
YDYingxue Ding
Yingxue Ding
YMYan Meng
Yan Meng
Mucopolysaccharidoses are a group of lysosomal storage disorders that are caused by deficiency of enzymes involved in glycosaminoglycans degradation. Due to low prevalence and high childhood mortality, researches on mucopolysaccharidoses were mainly focused on the fatal manifestations. With the development of treatments, more and more mucopolysaccharidoses patients were treated by approved therapies, thereby getting prolonged life span and improved quality of life. Abnormal accumulation of glycosaminoglycans in the eye may block trabecular meshwork, thicken sclera and change mechanical behavior of lamina cribrosa, which, by increasing intraocular pressure and damaging optic nerve, could cause glaucoma. Glaucoma was the leading cause of irreversible blindness worldwide, but it was rarely reported in mucopolysaccharidoses patients. Although non-fatal, it seriously affected quality of life. Prevalence of glaucoma in mucopolysaccharidoses patients (ranged from 2.1 to 12.5%) indicated that glaucoma in patients with mucopolysaccharidoses was worthy of attention and further study, thereby improving the quality of life for MPSs patients.